ADAR1 Capital Management »

Merus N V shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Merus N V (MRUS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Merus N V

Tip: Access up to 7 years of quarterly data

All positions including Merus N V held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Merus N V by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $660k 24k 27.50

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Merus N V

Commodore Capital
Federated Investors
Samlyn Capital
Deerfield Management Company
BVF
VR Adviser
Wellington Management Company
Boxer Capital
Franklin Resources
Balyasny Asset Management
Medicxi Ventures Management
Lynx1 Capital Management
venBio Select Advisor
Frazier Life Sciences Management
Fairmount Funds Management

View all funds holding Merus N V